Exhibit 99.1

Corporate Overview May 31, 2025

This presentation contains forward - looking statements about us, including our clinical trials and development plans, and our industry, that are based on management’s beliefs and assumptions and on information currently available to our management . The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” o r the negative of these terms o r other comparable terminology are intended to identify forward - looking statements, although not all forward - looking statements contain these identifying words . All statements, other than statements related to present facts o r current conditions o r of historical facts, contained in this presentation are forward - looking statements . Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including bu t not limited to that we have incurred significant operating losses, and we expect that we will incur significant operating losses for the foreseeable future ; that our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2025 , and a failure to obtain this necessary capital in the near term on acceptable terms, o r at all, could force us to delay, limit, reduce o r terminate our development programs, commercialization efforts o r other operations ; that we have a high risk of never generating revenue o r becoming profitable or, if we achieve profitability, we may not be able to sustain it ; that clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, and results of prior preclinical studies and early clinical trials are not necessarily predictive of future results, and elraglusib may not achieve favorable results in clinical trials o r preclinical studies, and we may not be able to make regulatory submissions o r receive regulatory approval on a timely basis, if at all ; that we may not successfully enroll additional patients o r establish o r advance plans for phase 2 o r other development, including through conversations with the FDA o r EMA and the standards such bodies may impose for such development ; that regulatory approval processes may involve delays, unfavorable determinations o r other challenges due to various factors, including government funding, staffing and political uncertainties ; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities and within the medical community ; that elraglusib could be associated with side effects, adverse events o r other properties o r safety risks, which could delay o r preclude regulatory approval, cause us to suspend o r discontinue clinical trials o r result in other negative consequences ; that this presentation includes preliminary and unpublished data which may be subject to change following the availability of more data o r following a more comprehensive review of the data and should not be relied upon as a final analysis ; that we do not have, and may never have, any approved products on the market and our business is highly dependent upon receiving approvals from various U . S . and international governmental agencies and will be severely harmed if we are not granted approval to manufacture and sell our product candidates ; our reliance on third parties to conduct our non - clinical studies and our clinical trials ; our reliance on third - party licensors and ability to preserve and protect our intellectual property rights ; that we currently depend entirely on the success of elraglusib, which is our only product candidate, and if we are unable to advance elraglusib in clinical development, obtain regulatory approval and ultimately commercialize elraglusib, o r experience significant delays in doing so, our business will be materially harmed ; that we face significant competition from other biotechnology and pharmaceutical companies ; that we may not be successful in our efforts to investigate elraglusib in additional indications and we may expend our limited resources to pursue a new product candidate o r a particular indication for elraglusib and fail to capitalize on product candidates o r indications that may be more profitable o r for which there is a greater likelihood of success ; that the termination of third - party licenses could adversely affect our rights to important compounds o r technologies ; and our ability to fund development activities , including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2025 , and a failure to obtain this necessary capital in the near term on acceptable terms, o r at all, could force us to delay, limit, reduce o r terminate our development programs, commercialization efforts o r other operations . You are cautioned not to place undue reliance on these forward - looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur o r circumstances that exist after the date hereof . In addition, any forward - looking statements are qualified in their entirety by reference to the factors discussed under the heading “Risk Factors” in our Annual Report on Form 10 - K filed with the SEC on March 13 , 2025 , our Quarterly Report on Form 10 - Q for the quarter ended March 31 , 2025 , filed with the SEC on May 15 , 2025 , and other filings with the SEC . This presentation also contain estimates and other statistical data that we obtained from industry publications and research and studies conducted by third parties relating to market size and growth and other data about our industry . This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates . 1 Forward - Looking Statements

2 IPO: August 2024 HEADQUARTERS: Fort Worth, TX Advancing a potentially class - leading GSK - 3 β inhibitor, elraglusib with a novel, multimodal MOA, in multiple advanced cancer Phase 2 trials Clinical responses (CRs/PRs) and Disease Control observed across cancer histologies Extended survival and increased responses are observed in mPDAC and relapsed/refractory Ewing sarcoma. Preliminary evidence of clinical benefit has also been observed in patients with metastatic melanoma and relapsed/refractory colorectal and lung cancer Oral version of elraglusib successfully evaluated in Healthy Volunteer Phase 1 • Phase 1 dose escalation study planned in advanced cancer patients Broad composition of matter IP protection and development incentives • Orphan Drug Designations for pancreatic and other cancer types; Fast Track Designation for pancreatic cancer Company Highlights NASDAQ: ACTU

3 Decreased immune evasion T Cells and NK Cells Activation Reduction of fibrosis Accumulation of activated T cells in and through str o m A a Inhibition of epithelial - mesenchymal transition (EMT) Inhibition of cell proliferation and survival Apoptosis GSK - 3 β Elraglusib: Multimodal MOA Supported by Clinical Data • Elraglusib is an ATP - competitive inhibitor of GSK - 3 β • GSK - 3 β has been shown to potentially contribute to tumor progression in many treatment naive and refractory/resistant tumors • Pleiotropic effects as signaling adaptor • Elraglusib downregulates well - credentialed molecular pathways that can lead to chemotherapy and drug resistance • NF - kB pathway - anti - apoptotic protein expression • Alterations in TGF - b and pro - inflammatory cytokines suggest role in fibrosis in addition to immunomodulation • DDR pathways (ATR/ATM) including mismatch repair (PMS2) • Increase responsiveness of resistant/refractory tumors to chemo and immune therapy - ”cold” tumors turned to “hot” • Inhibition of oncogenic epithelial - mesenchymal transitions DDR: DNA Damage Response Source, Walz et al., Clinical Cancer Research 2017; DOI: 10.1158/1078 - 0432. elraglusib

4 Milestones Phase 3 Phase 2 Phase 1 Preclinical Program Elraglusib Injection (IV) - ASCO presentation of topline data: Q2 2025 - FDA Type B pre - NDA meeting request: 2H 2025* Adult Actuate - 1801 Part 3B Pancreatic Cancer (with GnP) 1st line metastatic In Planning TBD** Adult – Phase 3 or Confirmatory Trial (if required)* Pancreatic Cancer (with GnP) 1st line metastatic Topline Data: 2H 2025 Pediatric Actuate - 1902 Advanced Refractory Cancers - Ewing Sarcoma Cohort Only Elraglusib (oral tablet) TBD** TBD** In Planning In Planning Adult Actuate - 2401 Adult /Pediatric Phase 1 in Advanced, refractory solid cancers Advanced, refractory cancers (solid and hematological) Strategic Pipeline Growth for GSK - 3 β Associated Diseases * The Company plans to request a pre - NDA meeting with the FDA in the second half of 2025 to align on a path towards product registration **Contingent upon future funding GnP: gemcitabine/nab - paclitaxel Ongoing Trial Fast track designation

5 Phase 1/2 Study Design for Elraglusib Injection (IV) Establishes process for transition from elraglusib (9 - ING - 41) Monotherapy (Part 1) to evaluation of multiple chemotherapy combinations (Part 2) to Phase 2 efficacy studies (Part 3) under one protocol 1 Clinical Study Actuate - 1801 1 Database for 1801 Parts 1 - 3A locked; final CSR in development GnP: gemcitabine/nab - paclitaxel Avg 3+ lines prior therapy (n=67) BOR: CR, PR, SDs DCR (16 wks): 42% 48% of patients went on to subsequent therapies Simon Two - Stage Trial (International) Randomized Controlled Trial (International) 1801 - Part 1 Elraglusib FIH Monotherapy Dose Escalation 1801 - Part 2 Elraglusib Dose Escalation in Combination with Standard Dosing Chemotherapy All patients required to have previously failed the combination chemo prior to enrollment Elraglusib + Gemcitabine Elraglusib + GnP Elraglusib + Carboplatin Elraglusib + Lomustine Elraglusib + Irinotecan Elraglusib + Paclitaxel Carboplatin Elraglusib + Doxorubicin Elraglusib + Pemetrexed Carboplatin 1801 - Part 3 Company Sponsored Phase 2 Studies 1801 - Part 3A First Line mPDAC GnP + elraglusib 1801 - Part 3B First Line mPDAC GnP + elraglusib

6 Elraglusib Opportunity Novel GSK - 3 β inhibitor that targets multiple molecular pathways in cancer cells but also impacts the TME and immune response Pancreatic Cancer Metastatic pancreatic cancer is highly aggressive and accounts for approximately 80 - 85% of all pancreatic cancer diagnoses. Projected market growth to >$5 billion by 2030 Survival Rate and Economic Burden The prognosis remains poor with a 5 - year survival rate of less than 10% and a high economic burden with annual treatment costs exceeding $100,000 per patient Current Treatment FOLFIRINOX and gemcitabine with nab - paclitaxel (GnP) are standard but offer limited survival benefits. Elraglusib is currently in clinical trials with FOLFIRINOX and GnP Elraglusib Potential in Metastatic Pancreatic Cancer (mPDAC) Pancreatic Cancer Treatment Market Size Report, 2030, https://www.grandviewresearch.com/industry - analysis/pancreatic - cancer - treatment - market ; Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, Gao. World J Gastroenterol. 2021 Jul 21;27(27):4298 - 4321. doi: 10.3748/wjg.v27.i27.4298. PMID: 34366606; PMCID: PMC8316912. Soefje SA. Managing the economic impact of advanced pancreatic cancer. Am J Manag Care. 2019 Jan;25(1 Suppl):S11 - S16. PMID: 30681820.

7 Phase 2 – Clinical Activity with Extended Median Overall Survival • 1801 Part 3A in mPDAC • Simon’s Two - Stage trial design - Stage 1 • Evaluate the combination of elraglusib and gemcitabine/nab - paclitaxel (GnP) • mOS of 15.3 (EE population) • 2 CRs confirmed • 9 PRs confirmed • DCR: 52%, ORR: 38% • Met Simon’s stage 1 threshold of DCR>50% • 42 total patients enrolled (ITT) Wainberg, Zev A et al., The Lancet, Volume 402, Issue 10409, 1272 – 1281; https:// www.ncbi.nlm.nih.gov/pmc/articles/PMC4631139/ mPDAC: metastatic pancreatic ductal adenocarcinoma; mOS: median overall survival; EE: efficacy evaluable; CR: complete response; PR: partial response; DCR: disease control rate; ORR: overall response rate; ITT: intent to treat The encouraging preliminary efficacy prompted a pivot to a randomized Phase 2 trial 100 80 60 40 20 0 - 20 - 40 - 60 - 80 - 100 Subject *13 subjects had no response data entered ■ Complete Response ■ Partial Response ■ Stable Disease ■ Progressive Disease Waterfall - Best Overall Response Kaplan Meier – Overall Survival (EE) 29 Subjects 21 (72%) Event 8 (28%) Censored 15.26 Median Survival (7.895, 18.13) 95% CL Survival Probability % Change from Baseline 0.8 0.6 0.4 0.2 0.0 1.0 0 6 1 2 1 8 2 4 Censored 3 0 Months 2 CRs and 100% PR

8 2:1 Randomization R ≥ 18 yrs old with metastatic pancreatic adenocarcinoma Participants must have measurable disease as defined by RECIST1.1 No prior therapy Total enrollment: 286 Inclusion Criteria Endpoints Primary endpoints: I year OS/mOS Secondary endpoints: ORR, DOR, PFS Sample size based on projected increase in 1 year survival from 35% in GnP to 55% in elraglusib/GnP with α =0.05; 232 patients needed for 80% power Randomized Treatment Elraglusib + GnP GnP alone Follow Up Survey 1801 - Part 3B: Phase 2 RCT in First - Line Metastatic PDAC RCT: randomized, controlled trial; PDAC: pancreatic ductal adenocarcinoma; OS: overall survival; ORR: overall response rate; DOR: duration of response; PFS: progression - free survival, FPD: First Patient Dosed 60 Global Sites FPD: August 2021 Enrollment Completion: January 2024 Topline Data: Reported at ASCO 2025 EU 18 US 36 Canada 6

9 PDAC: A Disease with Urgent Unmet Needs • Most patients with PDAC present with advanced or metastatic disease with poor survival • Median survival remains < 1 year, with real world data for mOS ranging from 6 - 9 months • Apart from PARP inhibitors as maintenance therapy in a subset of patients with gBRAC1/2 metastatic PDAC patients, there is an urgent need for more novel therapeutic targets for PDAC patients 1 year OS (%) mOS (months) Comparison Study 35.0 vs 22.0 8.5 vs 6.7 HR 0.72 ; p< 0.001 GnP vs Gem MPACT (Von Hoff et al. 2013) 39.5 vs 45.6 9.2 vs 11.1 HR 0.83 ; p< 0.036 GnP vs NALIRIFOX NAPOLI - 3 (Wainberg et al., 2024) N/A 6.87 vs 9.27; p< 0.001 GnP vs FFX retrospective, nonrandomized Klein - Brill et al. (2022) N/A GnP 6.9 (3.6 - 9.8) FFX 9.2 (4.7 - 11.4) GnP and FFX Real - world review Cockrum et al. (2025)

10 Predefined Safety Population Draft unaudited data as of March 27, 2025 The final data and results may change as the study continues through completion Phase 2 RCT Patient Demographics Elraglusib + GnP (n=155) GnP (n=78) Demographics Sex 75 (48.4%) 35 (44.9%) Female 80 (51.6%) 43 (55.1%) Male Age (years) 155 (100%) 78 (100%) n (%) 65.1 (9.1) 66.2 (9.9) Mean (S.D.) 65.0 68.0 Median 42.0, 86.0 42.0, 85.0 Min, Max Race 5 (3.2%) 2 (2.6%) Asian 7 (4.5%) 6 (7.7%) Black or African American 128 (82.6%) 65 (83.3%) White 1 (0.6%) 0 Multiracial 14 (9.0%) 5 (6.4%) Unknown/Not Reported Ethnicity 8 (5.2%) 0 Hispanic or Latino 141 (91.0%) 77 (98.7%) Not Hispanic or Latino 6 (3.9%) 1 (1.3%) Unknown/Not Reported Body Surface Area (BSA) (m2) 154 (99.4%) 78 (100%) n (%) 1.82 (0.22) 1.83 (2.23) Mean (S.D.) 1.81 1.82 Median 1.30, 2.41 1.31, 2.77 Min, Max Elraglusib + GnP (n=155) GnP (n=78) Demographics Eastern Cooperative Oncology Group Performance Status 64 (41.3%) 31 (39.7%) 0 89 (57.4%) 45 (57.7%) 1 2 (1.3%) 2 (2.6%) 2 Disease Status 109 (70.3%) 59 (75.6%) Metastatic at Initial Diagnosis 154 (99.4%) 77 (98.7%) Metastatic at Study Entry Site of Metastases 123 (79.4%) 68 (87.2%) Pancreas 112 (72.3%) 61 (78.2%) Liver 69 (44.5%) 27 (34.6%) Lymph Node 58 (37.4%) 26 (33.3%) Lung RCT: randomized, controlled trial

11 Study 1801 Part 3B Meets Primary Endpoint of Improved Survival PDAC: pancreatic ductal adenocarcinoma; OS: overall survival; ORR: overall response rate; DCR: disease control rate; PFS: progression - free survival Elraglusib/GnP (155) GnP (78) 10.1 7.2 Primary Endpoint: mOS (months) HR=0.63; log - rank p=0.01 44.1 22.3 12 month OS (%) p=0.0005 114 (73.5%) 70 (89.7%) Events (% events) 19.7 4.4 18 - month OS (%) 13.8 0 24 - month OS (%) 5.6 5.1 mPFS (months) HR=0.90; P=NS 136 (87.7%) 75 (96.2%) Events (% events) 61.3% 56.4% DCR 45 (29.0%) 17 (21.8%) ORR n (%) Predefined Safety Population Draft unaudited data as of March 27, 2025 mOS, p=0.01 Doubling of 1 year OS and 37% Reduction in Risk of Death vs GnP Elraglusib + GnP mOS, p=0.01 Elraglusib + GnP The final data and results may change as the study continues through completion

12 Administrative Analysis of 1801 Part 3B OS Swim Plot The final data and results may change as the study continues through completion GnP + weekly elraglusib: n=155 (8 on treatment, 114 events) GnP : n= 78 (0 on treatment, 70 events) Predefined Safety Population Draft unaudited data as of March 27, 2025

13 Predefined Safety Population Data as of March 27, 2025 Phase 2 RCT in First - Line Metastatic PDAC - Best Overall Response The final data and results may change as the study continues through completion. 1801 Part 3B: GnP + Weekly Elra Best Overall Response 1801 Part 3B: GnP Best Overall Response * ** *Patient had a partial response on treatment, then was referred for a Whipple procedure and subsequently came off treatment **Patient had a partial response on treatment, then was referred for a Whipple procedure and then reported a complete response with 100% of the primary tumor removed

14 Elraglusib + GnP Data Show OS Benefit Across Key Subgroups The final data and results may change as the study continues through completion Predefined Safety Population Data as of April 27, 2025 Draft unaudited data Elraglusib + GnP Better Elraglusib + GnP,

15 The final data and results may change as the study continues through completion Subgroup of Patients Treated for One Cycle (4 weeks) - Significant Benefit in OS PDAC: pancreatic ductal adenocarcinoma; OS: overall survival; ORR: overall response rate; DCR: disease control rate; PFS: progression - free survival Elraglusib/GnP (116) GnP (58) 12.5 8.5 Primary Endpoint: mOS (months) HR=0.57; log - rank p=0.018 52.5 28.3 12 - month OS (%) 85 (73.3%) 50 (86.2%) Events (% events) 21.5 0 18 - month OS (%) 12.1 0 24 - month OS (%) 6.9 5.6 mPFS (months) HR=0.78; P=NS 105 (90.5%) 55 (94.8%) Events (% events) 53.4% 44.8% DCR 44 (37.9%) 17 (29.3%) ORR n (%) Predefined Safety Population Draft unaudited data as of March 27, 2025 Near Doubling of 1 year OS and 43% Reduction in Risk of Death vs GnP Elraglusib + GnP mOS, p=0.018

16 Patients with Liver Metastases - Significant Benefit in mOS and mPFS 2.5X Increase in 1 Year Survival and a 38% Reduction in Risk of Death Elraglusib/GnP (114) GnP (61) 8.3 6.6 Primary Endpoint: mOS (months) HR=0.62; log - rank p=0.008 39.2 15.2 12 month OS (%) p=0.0003 92 (80.7%) 56 (91.8%) Events (% events) 13.6 0 18 - month OS (%) 0 0 24 - month OS (%) 4.9 3.9 mPFS (months) HR=0.72; P=0.039 104 (91.2%) 59 (96.7%) Events (% events) 36.8% 27.9% DCR 34 (29.8%) 12 (19.7%) ORR n (%) Predefined Safety Population Draft unaudited data as of March 27, 2025 * z - test PDAC: pancreatic ductal adenocarcinoma; OS: overall survival; ORR: overall response rate; DCR: disease control rate; PFS: progression - free survival mOS, p=0.008 Elraglusib + GnP The final data and results may change as the study continues through completion

17 Subsequent Anti - Cancer Therapy Predefined Safety Population Draft unaudited data as of March 27, 2025 LV - leucovorin * this patient also received anti - neoplastic therapy with radiation ** Other primarily represents various other chemotherapy regimens The final data and results may change as the study continues through completion Elraglusib/GnP GnP (155) (78) 78 (50%) 37 (47.4%) Subsequent anti - cancer therapy (%) 78 (50%) 36 (46%) Systemic anti - neoplastic therapy 23 (28%) 13 (35%) FOLFIRINOX 0 (0%) 1 (3%) FOLFOX 7 (9%) 3 (8%) FOLFIRI 10 (13%) 3 (8%) GnP 7 (9%) 3 (8%) 5 - FU/liposomal irinotecan/LV 31 (40%) 13 (36%) Other ** 0 (0%) 1 (3%)* Radiotherapy

18 Actuate 1801 Part 3B (ongoing) TEAEs of Any Grade Reported in 20% of Patients Treated with elraglusib Safety Profile of Elraglusib in Combination with GnP • Overall rate of a TEAE and/or an SAE observed were similar in the elraglusib + GnP - treated patients as compared to GnP - treated patients • Treatment discontinuation due to TEAEs were similar across the treatment groups • Visual impairment and fatigue were major TEAEs attributed to elraglusib as a single agent in 1801 Part 1 and were mild to moderate in the 1801 3B 1 • Transient visual impairment described as transient alterations in color and skin tones under fluorescent light • No permanent changes to eye structure or vision Key Takeaways 1 Carneiro et al. Clin Cancer Res 2024 Feb 1;30(3):522 - 531 *Includes Preferred Terms (PT) neutropenia and neutrophil count decreased ** Includes PT anemia and hemoglobin decreased ***Includes PT thrombocytopenia and platelet count decreased Predefined Safety Population Draft unaudited data as of March 27, 2025 TEAE: Treatment - Emergent Adverse Event The final data and results may change as the study continues through completion

19 mOS (1801) Key Histologies Combination 9.1 months CPI Refractory, Metastatic Melanoma Elraglusib Monotherapy 6.9 months Refractory, metastatic Colorectal Elraglusib/Irinotecan ND CPI/Platinum refractory, metastatic NSCLC Elraglusib/Carboplatin 12 weeks on elraglusib leads to Complete Response by PET - MRI. Cystic lesions observed in place of prior tumor. Clinical Activity in Areas of High Unmet Need in 1801 Part 1 and 2 Actuate 1801 Part 1 evaluated elraglusib as a single agent • First objective response reported in patient treated with 5 mg/kg elraglusib monotherapy • Metastatic melanoma diagnosed in 2018; widely metastasized to the brain, lungs, bones, muscles, stomach, lymph nodes, pancreas and adrenal glands • Refractory to all FDA - approved standard therapies, including several checkpoint inhibitors and BRAF / MEK inhibitor • After 12 Weeks on elraglusib: Brain MRI showed complete response (CR) by RANO criteria, PET scan showed complete metabolic response (“CMR”) • Durable CMR ongoing (OS >5.5 years as of November 15, 2024) Refractory, metastatic melanoma identified as a clinical indication for elraglusib development • A second patient receiving single - agent elraglusib has ongoing stable disease (SD) (3.1 years as of last documented alive date) • Also failed all FDA - approved standard therapies including immune checkpoint inhibitors and several experimental treatments • Patients receiving chemotherapy salvage after anti - PD - 1 treatment have a mOS of 6.9 months across all chemotherapy tested • Potential for genomic biomarker enrichment to improve the probability of success based on ML models of CPI response Goldinger at el., Eur J Cancer 2022; 162: 22.

20 Elraglusib Oral Formulations Provide Similar Drug Exposures to IV • Decreased cost of manufacturing at commercial scale compared to IV formulations • Phase 1 Study of Oral Solution in Normal Healthy Volunteers (NHV) showed > 50 % bioavailability vs IV after a single dose • Exposure and pharmacodynamic effects exhibited in fed/fasted patients • Oral Solid > 95 % bioavailability vs IV when dosed with food • Phase 1 dose escalation study using Elraglusib Oral Tablet in advanced cancer patients (not healthy volunteers) in planning stage Elraglusib Arithmetic Mean Concentration - Time Profiles

21 Key Near Term Anticipated Development Plans and Milestones For Accelerating Registration in mPDAC 2026 2025 Jan Mar Jun mPDAC: Initiate planning of Phase 3 or Confirmatory Trial mPDAC: Phase 2 Topline data mPDAC: Part 3A publication mPDAC: ASCO Presentation Sep Dec mPDAC: FDA Type B pre - NDA Meeting to discuss P2 data supportive NDA 2 1: Referencing IND previously filed with DO2 2: Contingent on future discussions with the FDA and future funding mPDAC: Initiate Phase 3 or Confirmatory Trial (if required) 2 Jan Jun mPDAC: Start Rolling / RTOR NDA (P2 Data) 2 mPDAC: DO3 IND Submission 1 mPDAC: FDA Type B pre - NDA Meeting Request

22 Steven D. Reich, MD – Sr VP, Clinical Development and Acting Chief Medical Officer • Oncology drug development executive leader for commercial clinical development and strategy • Directed multi - national medical research groups within pharmaceutical/biotechnology companies and CRO • Lead investigator for Phase I - III trials and designed and managed Phase I - IV trials for industrial sponsors • Headed the clinical research programs leading to multiple US, Canadian, and European drug approvals • Epogen, Targretin, Panretin, Fludara, Inlyta Seasoned and Successful Leadership Experienced leadership team with demonstrated ability to develop and commercialize cancer drugs Daniel M. Schmitt – Chief Executive Officer and Founder • 30+ years of biotechnology and pharmaceutical experience across senior executive roles • Led and contributed to the successful development and launch of multiple pharmaceutical products • Exosurf, Zovirax, Valtrex, Adenoscan, Ambisome, Duraclon, Campath, Abraxane, enTrust • Executed ~1B+ in milestone value through licensing, acquisition, and development deals Andrew Mazar, PhD – Chief Operating Officer and Scientific Co - Founder • Co - founder, Chief Scientific Officer and Director, Monopar Therapeutics, Inc. (Nasdaq: MNPR) • Entrepreneur - in - Residence; Professor of Pharmacology; Founding Director, Center for Developmental Therapeutics, Northwestern University • Chief Scientific Officer, Attenuon, LLC • Internationally recognized expert in cancer metastasis and translational oncology • Eleven drugs from discovery through Phase 2 • >250 peer - reviewed publications and book chapters and inventor on > 70 patents • Serial entrepreneur with seven start - ups founded Paul Lytle – Chief Financial Officer • 30+ years of finance and accounting experience • 25+ years of public company experience for Nasdaq listed companies • Served as co - founder, CFO, and director for multiple biotech companies • Raised in excess of $500 million in net proceeds from various equity and debt offerings

23 Extensive data on activity from leading research institutions and promising clinical data in multiple cancer histologies Developing elraglusib to address therapeutic shortcomings in key difficult - to - treat and refractory tumors Focus on mediating cancer cell survival and chemoresistance through regulation of NF - kB and regulating antitumor immune response Expansive, global patent portfolio with significant exclusivity runway Multiple key regulatory designations available (Fast Track, Orphan Drug) with registration path clinical trials underway and in development Distinguished leadership and recognized world leading scientific advisory team Leading Therapeutic Profile Significant Unmet Needs Complementary Mechanisms of Action Robust IP Portfolio Clearly Defined Regulatory Path Seasoned Leadership Team Investment Highlights

The Passion to Pursue More